ClinicalTrials.gg
CompletedNCT02231190Updated May 9, 2017

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

A Phase 1 interventional study of GSK1278863 and Placebo in Tendon Injuries, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Tendon Injuries with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Tendon Injuries · United States.

Enrollment
10th of 18
26 · median 28
Started
2015
with 1 other
Phase 1
Only one
of the 23
Registered
8th of 23
by date
Lead sponsor
1 of 23
GlaxoSmithKline

Among the 23 studies in Tendon Injuries with a site in United States, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2015, is the only one in phase 1, and was the 8th registered.

Tendon Injuries

100 studies on the registry are indexed under Tendon Injuries; 27 are open to participants now.

Browse Tendon Injuries studies →

Open to participants now

4 of the 23 studies in Tendon Injuries with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Tendon Injuries studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Tendon Injuries with a site in United States, or all of them as a file.
02

Study summary

As per non-clinical studies, prolyl hydroxylase inhibitor GSK1278863 can protect muscle from unaccustomed exercise induced muscle damage and enhance functional muscle repair. This study is designed to investigate arm function, pain and other pharmacodynamic (PD) markers after unaccustomed maximal eccentric exercise with concurrent administration of GSK1278863 or placebo. Primary objective of the study is to evaluate the protective effects of GSK1278863 on eccentric exercise induced muscle injury. Subjects will be randomized in a 1:1 ratio (1 subject on GSK1278863 for every 1 subject on placebo). Each subject will be given five oral doses of GSK1278863/placebo in total. The first dose will be administered immediately after completion of eccentric exercise and then 4, 8, 24, and 48 hours later. Subjects will be housed till day 4 in unit and will return for a follow-up visit 7-10 days after discharge. After enrolment of approximately 30 subjects, enrolment will be paused and planned interim analysis will be performed to decide whether to terminate enrolment/study, continue dosing or to reduce the dose to 5 milligrams (mg).

03

Conditions studied

  • Tendon Injuries

Keywords

  • muscle soreness
  • Muscle damage and recovery
  • muscle function
  • eccentric exercise
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply:
  • Males between 18 and 35 years of age inclusive, at the time of signing the .
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with values outside the normal range should always be excluded from enrolment.
  • Body weight >= 70 kilogram (kg) and (BMI) within the range 22.0 to 34.0 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • (ALT), alkaline phosphatase and \<= 1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • interval (QTc) \< 450 milliseconds (msec) based on single or average QTc value of triplicate values obtained over a brief recording period. The QT correction formula (Fridericia's) used to determine inclusion and discontinuation should be the same throughout the study.
  • At least a 1year history of no regular (2-3 times per week) exercise and no heavy exertion within past week, and in the examining physician's opinion the study participant's physical condition/physique is consistent with a history of no regular physical activity for the past year.
  • No strenuous exercise involving the arms during the last 10 weeks (e.g., resistance training, rock climbing, rowing, chopping wood, digging, shovelling, sawing).
  • The subject is mentally and legally able to comply with the requirements and restrictions of the protocol and has provided signed informed consent prior to participation in any protocol-specific procedures, including Screening procedures.

Exclusion criteria

Exclusion Criteria:

  • A subject will not be eligible for inclusion in this study if any of the following criteria apply:

Criteria Based Upon Medical History

  • History of dizziness or vertigo.
  • Uncontrolled hypertension [diastolic blood pressure (BP) >100 millimeter of mercury (mmHg) or systolic BP >170mmHg] at Screening.
  • Taking anti-inflammatory, or other pain medication more than 2 times per week over the previous month.
  • Unwilling to abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements), within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until completion of the follow-up visit, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study.
  • History of regular alcohol consumption within 6 months of the study defined as:

An average weekly intake of >14 drinks for males. One drink is equivalent to 12 grams(g) of alcohol: 12 ounces [360 milliliter (mL)] of beer, 5 ounces (150mL) of wine or 1.5 ounces (45mL) of 80 proof distilled spirits.

  • History of drug abuse or dependence within 6 months of the study.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation.
  • History of peptic ulcer disease or upper gastrointestinal (GI) bleeding within the past 6 months.
  • History of thrombosis defined as deep vein thrombosis, stroke, pulmonary embolism or other thrombosis related condition within 3 months prior to Screening.
  • History of myocardial infarction or acute coronary syndrome within 3 months prior to Screening.
  • History of stroke or within 3 months prior to Screening.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of GSK1278863. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue. Examples of conditions that could interfere with hepatic function include Gilbert's syndrome.
  • Evidence of active peptic, duodenal or esophageal ulcer disease at Screening OR history of GI bleeding within 3 months prior to Screening.
  • Subjects with chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease).
  • Subjects with a history of symptomatic right heart failure.
  • Subjects with Class III or Class IV heart failure, as defined by the (NYHA) functional classification system.
  • History of proliferative vascular eye disease (e.g., choroidal or retinal disease, such as neovascular age-related macular degeneration, proliferative diabetic retinopathy or macular edema) based upon having had an ophthalmologic exam within 12 months prior to Screening.
  • History of risk factors for hypercoagulable state:
  • Factor V Leiden (the most common)
  • Prothrombin gene mutation
  • Deficiencies of natural proteins that prevent clotting (such as antithrombin III, protein C and protein S)
  • Recent vascular trauma or surgeryd
  • Central venous catheter placement
  • Obesity
  • Antiphospholipid antibody syndrome
  • Myeloproliferative disorders such as polycythemia vera or essential thrombocytosis
  • Paroxysmal nocturnal hemoglobinuria
  • Nephrotic syndrome
  • Active or diagnosis of malignancy within 5 years prior to Screening (excluding successfully treated basal or squamous cell carcinoma).

Criteria Based Upon Diagnostic Assessments

  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • A positive test for antibody.
  • Screening level > 17.0 grams per deciliter (g/dl).
  • Screening Creatine phosphokinase (CPK) > 5xULN.
  • Screening serum creatinine >1.10. Other Criteria
  • Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56-day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the and as directed by site staff.
  • Subject is either an immediate family member of a participating Investigator, study coordinator, employee of an Investigator; or is a member of the staff conducting the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    GSK1278863

    Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours

    Drug: GSK1278863

  • Placebo comparator
    Placebo

    Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours

    Drug: Placebo

Interventions

  • GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise

  • DrugPlacebo

    GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise

06

What researchers measure

Primary outcomes

  1. Maximal voluntary contraction (MVC) following eccentric exercise in subjects treated with GSK1278863 or placebo

    Muscle strength is a measure of the amount of force produced during a maximal voluntary contraction of the elbow flexors. It will be assessed in the non-dominant arm by a maximal isometric (fixed length) contraction using Cybex ergometer in a seated position after completion of eccentric exercise

    Time frame: Up to 72 hours (hrs)

Secondary outcomes

  1. Change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo

    Change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed

    Time frame: Up to 72 hrs

  2. Percent change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo

    Percent change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed

    Time frame: Up to 72 hrs

  3. Number of subjects with adverse events(AE)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

    Time frame: Up to Day 15

  4. Vital signs assessment as a safety measure

    Vital signs includes systolic and diastolic blood pressure, pulse rate and respiratory rate

    Time frame: Up to Day 15

  5. Electrocardiogram (ECG) assessment as a safety measure

    Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, Total cardiac output (QT), and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals

    Time frame: Up to Day 15

  6. Laboratory parameters assessment as a safety measure

    Laboratory parameters include hematology, clinical chemistry, and urinalysis

    Time frame: Up to Day 15

  7. Change in subject pain assessment using a visual analog scale

    Arm pain will be assessed for the exercised arm with a visual analog scale on a scale of 0-100 millimeter (mm) during two stimuli; during passive stretching and during MVC contraction, post-exercise and after completion of eccentric exercise

    Time frame: Up to 72 hrs

  8. Change in degree of motion and resting arm angle from post-exercise

    Subjects will be asked to maximally flex their elbow and then maximally extend their elbow, joint angle will be measured using a manual goniometer at maximum flexion and maximum extension. Range of motion will be calculated by subtracting the flexion angle from the extension angle

    Time frame: Up to 72 hrs

  9. Composite of PK parameters

    PK parameters include maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), and Area under the concentration-time curve from zero (pre-dose) to 24h \[AUC(0-24)\]

    Time frame: Up to Day 2

07

Study locations

1 site
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jun 2015, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2014
First posted
Sep 4, 2014
StartActual
Jan 15, 2015
Primary completionActual
Jun 12, 2015
CompletionActual
Jun 12, 2015
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02231190
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 4, 2014
Start date
Jan 15, 2015
Primary completion
Jun 12, 2015
Completion
Jun 12, 2015
Last update
May 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion